Companies Directory

Crystal Vision makes infrastructure and keying products for professional broadcast engineers in the television industry. Crystal Vision helps people transition through a range of technologies, from SD to HD and from HD to IP. The modular products include real-time chroma keyers, logo keyers, squeeze back keyers, up and down converters, synchronisers, video and audio converters, video and audio distribution amplifiers, video and audio delays, colour correctors, fail-safe routing switches, audio embedders/de-embedders, fibre optic transmitters and receivers and IP gateways. Crystal Vision offers two frame systems: 'Indigo'​ for the biggest range of boards and three frame sizes and the forward-looking 'Vision'​ for those planning a video over IP or 4K installation, or whose SDI system would benefit from dual syncs and extra outputs. Offering responsive support from its UK and USA offices, as well as product reliability, competitive pricing, fast delivery times and a five year warranty, Crystal Vision is a company that people like dealing with.

We help our partner organizations companies make better decisions, convert those decisions to meaningful actions and deliver sustainable and profitable success.

CrystalGenomics is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for global development in California, and it is publicly traded on the KOSDAQ exchange (083790). CrystalGenomics has a product on the market and is developing several novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation NSAID for the treatment of signs and symptoms of osteoarthritis. The first clinical stage program is CG-745, an epigenetic agent applicable to various types of solid and liquid tumors and currently, phase 2 clinical trials are ongoing for pancreatic cancer and MDS. The second clinical stage program is CG-549, a novel class antibiotic for MRSA where its phase 2a skin infection study in the US had been completed with a positive outcome of 100% clinical cure rate. The Company's therapeutic candidates are discovered and developed through its proprietary discovery platform technology which utilizes the integrated technologies of the SPS™ (technology for structure determination), the SCP™ (technology for the generation of lead compounds) and the SDF™(technology used for lead optimization) technologies. By leveraging its capabilities and the know-how in novel drug discovery and development, CrystalGenomics will continue to strive in making significant contributions for improving human health. For more information, please visit: www.cgxinc.com or www.crystalgenomics.com.

Crystalise is a trusted partner in transformational asset management for asset-intensive industries including energy, minerals & metals, and infrastructure. We deliver integrated solutions across Advisory, Specialist, and Operational Services, enabled by agile digital innovation. With a team of 60+ experts and a strong global presence spanning Australia, Africa, the Americas, and beyond, we bring deep operational insight, predictive analytics, and robust data governance to every project. Our customised solutions improve reliability, optimise performance, and unlock long-term value—driving excellence for clients worldwide.

Crystalline is into software development with passion. We eat code for breakfast with a hot cup of syntax. Nerdy? Yes. Reliable? Yes. Honest? Always! We are polyglot developers (JS, Ruby, Go, Java, ...). We focus on understanding before solving problems.